Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This review reports the incidence of hyperprolactinemia, its relationship with genotype, and prolactin-related side effects in children and adolescents treated with antipsychotics. METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Twenty-nine studies were selected after a literature search in the English Medline/Embase/Psychinfo/EBM databases (1965 to August, 2008). RESULTS: All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from baseline values of 8.0 ng/mL to 25-28 ng/mL after 4 weeks of treatment (reference range 0-15 ng/mL). The most and best data are available for risperidone. Five risperidone studies (n = 577) show an increase of prolactin level from 7.8 ng/mL to 17.7 ng/mL after 1 year of treatment, and two risperidone studies (n = 60) show an increase from 7.4 ng/mL to 24.9 ng/mL after 2 years of treatment. Aggregated over all antipsychotics, prolactin-related side effects, such as gynecomastia, galactorrhea, irregular menses, and sexual dysfunction, were reported by 4.8% of the children and adolescents. No data are available on bone mineral density in relation to antipsychotic-induced hyperprolactinemia in children and adolescents. Prolactin levels may be influenced by the genetic differences that influence prolactin metabolism and D2 dopamine receptor density. CONCLUSION: Persistent elevation of prolactin for periods up to 2 years has been documented in maintenance treatment with risperidone. Very limited long-term data of pimozide, olanzapine, and quetiapine prohibit drawing conclusions for these antipsychotics. Systematic long-term observational studies, including specific questionnaires as well as physical examination, are needed to investigate prolactin-related side effects of antipsychotic treatment in children and adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 1×
“…of risperidone and olanzapine appear to be effective in the treatment of behavioral problems in autism spectrum disorders (Malone et al. 2002; McCracken et al. 2002), conduct disorders (Findling et al. 2000; Aman et al. 2002; Snyder et al. 2002), and acute psychotic symptoms (Arango et al.…”
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Human brain dopamine receptors in children and aging adults
Seeman, P., Bzowej, N. H., Guan, H. ‐., Bergeron, C., Becker, L. E., Reynolds, G. P., Bird, E. D., Riederer, P., Jellinger, K., Watanabe, S., et al. (1987) · Synapse · doi:10.1002/syn.890010503 · Cited by 404
Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335 · cited 6×
“Further treatment showed a decrease to 17.7ng = mL (male 15.8ng = mL and female 20.8ng = mL) after 1 year of treatment (Turgay et al. 2002; Findling and McNa-mara 2004; Croonenberghs et al. 2005; Stevens et al. 2005; Anderson et al. 2007) and to 24.9ng = mL (male 24.6ng = mL and female 27.6ng = mL…”
InfluentialAntipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Meaney, A. M., Smith, S., Howes, O. D., O'Brien, M., Murray, R. M., & O'Keane, V. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.6.503 · Cited by 217 · cited 2×
“The induced hypogonadotropic hypogonadism together with low estrogen and testosterone levels may cause low bone mineral density and osteoporosis (Abraham et al. 2003a; Abraham et al. 2003b; Meaney et al. 2004; Hugenholtz 2005; O’Keane and Meaney 2005; Becker and Epperson 2006; Howard et al. 2007).”
Reduced bone cortical thickness in boys with autism or autism spectrum disorder
Hediger, M. L., England, L. J., Molloy, C. A., Yu, K. F., Manning-Courtney, P., & Mills, J. L. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0453-6 · Cited by 193
Risk of hip fracture in patients with a history of schizophrenia
Howard, L., Kirkwood, G., & Leese, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.023671 · Cited by 158 · cited 2×
“The induced hypogonadotropic hypogonadism together with low estrogen and testosterone levels may cause low bone mineral density and osteoporosis (Abraham et al. 2003a; Abraham et al. 2003b; Meaney et al. 2004; Hugenholtz 2005; O’Keane and Meaney 2005; Becker and Epperson 2006; Howard et al. 2007).”
Effects of Psychiatric Disorders and Psychotropic Medications on Prolactin and Bone Metabolism
Misra, M., Papakostas, G. I., & Klibanski, A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1205 · Cited by 156 · cited 1×
“The occurrence of osteopenia or osteoporosis correlates with the presence and duration of hypogonadism rather than the degree of hyperprolactinemia (Greenspan et al. 1989; Misra et al. 2004; O’Keane and Meaney 2005).”
Byerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153 · cited 2×
“In 2004, another review on prolactin and antipsychotic agents in children and adolescents was published (Pappagallo and Silva 2004), and in 2007 a review on prolactin elevation and antipsychotic treatment in adult patients with schizophrenia and bipolar disorders was published (Byerly et al. 2007).”
Meaney, A. M., & O'Keane, V. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.013 · Cited by 92
Abraham, G., Paing, W. W., Kaminski, J., Joseph, A., Kohegyi, E., & Josiassen, R. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1618 · Cited by 82 · cited 9×
“The effect of hyperprolactinemia on BMD was studied by comparing the results for two groups of patients with prolacti-nomas, one group of 20 adolescents and one group of 20 adults.”
InfluentialKnegtering, H., Boks, M., Blijd, C., Castelein, S., van den Bosch, R. J., & Wiersma, D. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230600666378 · Cited by 74 · cited 3×
“…value is related to the consequences of long-term hyperprolactinemia such as a decline in sexual function (Knegtering 2003; Knegtering et al. 2004; Knegtering et al. 2006; Costa et al. 2007; Nakonezny et al. 2007) and decreased BMD (Abraham et al. 2003a; Abraham et al. 2003b; Meaney and O’Keane…”
Paediatric uses of atypical antipsychotics
Findling, R. L., McNamara, N. K., & Gracious, B. L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.935 · Cited by 46 · cited 1×
“…olanzapine appear to be effective in the treatment of behavioral problems in autism spectrum disorders (Malone et al. 2002; McCracken et al. 2002), conduct disorders (Findling et al. 2000; Aman et al. 2002; Snyder et al. 2002), and acute psychotic symptoms (Arango et al. 2004; Sikich et al. 2004).”
Cited by
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Koch, M. T., Carlson, H. E., Kazimi, M. M., & Correll, C. U. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2023.03.007 · Cited by 31
Metadata
- Authors
- Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-08
- Volume
- 19
- Issue
- 4
- Pages
- 403-414
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2160412761
- Cited by
- 109
- References
- 15
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.